Arrowhead Pharmaceuticals, Inc. (ARWR) Financials

ARWR Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 2.3 billion 1.7 billion
Dec. 31, 2025 1.6 billion 1.0 billion
Sept. 30, 2025 1.4 billion 881.9 million
June 30, 2025 1.4 billion 860.8 million

ARWR Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 81.9 million 16.7 million
Dec. 31, 2025 11.3 million 19.4 million
Sept. 30, 2025 13.0 million 19.1 million
June 30, 2025 -157.1 million 13.0 million

ARWR Net Income

No data available :(

ARWR Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 1.8 billion 1.2 billion 100.1 million
Dec. 31, 2025 916.6 million 163.1 million 109.7 million
Sept. 30, 2025 919.4 million 214.9 million 111.4 million
June 30, 2025 900.4 million 560.6 million 105.7 million

ARWR Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 142.4 million
Dec. 31, 2025 140.7 million
Sept. 30, 2025 135.7 million
June 30, 2025 139.0 million

ARWR Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 2.6 million 167.4 million 41.2 million -
Dec. 31, 2025 2.1 million 177.2 million 45.5 million -
Sept. 30, 2025 7.5 million 174.7 million 37.2 million -
June 30, 2025 2.4 million 162.4 million 30.4 million -

ARWR Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 73.7 million 6.4 million
Dec. 31, 2025 264.0 million 6.4 million
Sept. 30, 2025 256.5 million 6.4 million
June 30, 2025 27.8 million 6.2 million

ARWR

Price: $76.82

52 week price:
14.30
82.26

Earnings Per Share: -2.24 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 594870

Ebitda: -12.7 million

Market Capitalization: 10.0 billion

Links: